Paris-based digital health insurance startup Alan raised €480M led by Prosus at a €5.5B valuation, and is set for €1B+ in annual recurring revenue by year's end
Paris-based group raises one of Europe's biggest non-AI start-up rounds this year
Context & Ripple Effects
Alan's financing history shows a sustained progression from a SaaS-focused private-health-insurance offering into a broader app-based model that included personalized mental-health programs. Its valuation moved from €1.4B in 2021 to €2.7B in 2022, €4B in 2024 and €5B in its March 2026 round.
The latest round extends that upward trajectory at a time when related coverage notes pressure on European unicorn valuations. It is also a notable financing event outside the AI category, with Prosus joining Alan's investor base after recent rounds led by Belfius and Index Ventures.
First-order effects
- Alan gains €480M of additional financing and a €5.5B valuation benchmark, strengthening its capital position relative to its earlier 2026 and 2024 raises.
- Prosus becomes the lead investor in Alan's latest round, while Alan's stated path to more than €1B in annual recurring revenue becomes the near-term operating milestone against which the company will be judged.
Second-order effects
- The round raises the funding and valuation bar for other digital-health-insurance companies seeking growth capital: investors now have a large, recent reference point for a scaled European operator outside AI.
- Alan's existing backers and prospective investors in adjacent health-benefits products will likely focus more sharply on recurring-revenue scale and retention evidence, rather than unicorn status alone, given the reported reassessment of European startup valuations.
Third-order effects
- If Alan converts its capital and revenue trajectory into durable scale, digital health insurance could increasingly be financed as a recurring-revenue software-and-services category rather than treated solely as a narrower insurance niche.
- The case suggests that late-stage European capital can still support large non-AI rounds, but the durability of that opening depends on whether companies can substantiate growth with recurring revenue as valuation scrutiny persists.
The trend: Alan is one data point in the selective return of large European growth financings for non-AI companies that can pair digital products with demonstrable recurring revenue.